Meeting
2021 ASCO Annual Meeting
Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.
Authors
Niven Mehra
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands
Niven Mehra , Karim Fizazi , Johann S. De Bono , Philippe Barthélémy , Tanya B. Dorff , Adam Patrick Stirling , Jean-Pascal H. Machiels , Davide Bimbatti , Deepak Kilari , Herlinde Dumez , Consuelo Buttigliero , Inge M. van Oort , Elena Castro , Hsiang-Chun Chen , Nicola Di Santo , Liza L DeAnnuntis , Cynthia G. Healy , Giorgio V. Scagliotti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03148795
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5047)
DOI
10.1200/JCO.2021.39.15_suppl.5047
Abstract #
5047
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).
First Author: Johann S. De Bono
Poster
2020 Genitourinary Cancers Symposium
TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).
First Author: Johann S. De Bono
Poster
2023 ASCO Genitourinary Cancers Symposium
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Neeraj Agarwal
Poster
2022 ASCO Annual Meeting
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene–mutated, metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Neeraj Agarwal